Turkey Grants Patent for GeneQuine’s Lead Products

Following Europe and China, the Turkish Patent Office grants the Patent for GeneQuine’s Lead Products.

The patent covers helper-dependent adenoviral vectors expressing interleukin-1 receptor antagonist and their use in the treatment of osteoarthritis. With the granted patent, GeneQuine secures intellectual property rights in the Turkish healthcare market, which has a large growth potential. Patent applications for this technology are pending in other regions of the world.